Clinical Trials Logo

Metastasis clinical trials

View clinical trials related to Metastasis.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 2

NCT ID: NCT04825470 Not yet recruiting - Liver Cancer Clinical Trials

Liver Transplantation for Unresectable GIST Liver Metastases

TRANSGIST
Start date: May 2022
Phase: N/A
Study type: Interventional

Liver Transplantation for Unresectable GIST Liver Metastases

NCT ID: NCT04683575 Not yet recruiting - Recurrence Clinical Trials

Clinical Study on the Effect of Selenium Yeast Capsule on Prognosis of Differentiated Thyroid Carcinoma

Start date: May 30, 2022
Phase: Phase 4
Study type: Interventional

Oxidative stress is involved in the pathogenesis of thyroid cancer, but the mechanism is not clear. The thyroid is the organ with the most abundant selenium content, and selenium may be involved in protecting the gland from the influence of large amounts of H2O2 produced during thyroid hormone biosynthesis. Selenium may exert anti-tumor activity through a variety of mechanisms, including inducing apoptosis and anti-oxidation to change the DNA methylation state of tumor suppressor genes, cell cycle arrest and stimulation of the immune system, as well as playing an anti-tumor role through its anti-inflammatory and anti-angiogenesis properties. The whole blood and thyroid selenium concentrations in patients with thyroid cancer were lower, and the decreased serum selenium levels were also associated with the high TNM stage of thyroid cancer. According to the Nutrition Prevention of Cancer (NPC) trial, selenium yeast supplements with a daily selenium content of 200 MCG have been shown to reduce the incidence of total cancer, prostate cancer, colon cancer, and lung cancer, and cancer mortality. The active agent in selenium yeast supplements is known as selenium methionine (SEMET). In general, the association between selenium and thyroid cancer is still inconclusive, the question of whether low selenium is a predisposition factor or a consequence of thyroid cancer has not been resolved, and the clinical effect of selenium supplementation in preventing thyroid cancer or improving its prognosis remains to be studied. The hypothesis is that supplementation with selenium yeast will improve the prognosis of patients with differentiated alpha-carcinoma.

NCT ID: NCT04351282 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal Carcinoma

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

Primary metastatic NPC patients received chemotherapy± immunotherapy, radiation for primary tumors and SBRT for metastatic lesions.

NCT ID: NCT03560856 Not yet recruiting - Breast Cancer Clinical Trials

A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer

PALPETBIO
Start date: June 27, 2018
Phase: Phase 2
Study type: Interventional

The clinical efficacy of fulvestrant and/or palbociclib in the population of patients with metastatic lesions harboring ESR1 mutations was reported. In the PALOMA 3 study, the combination of Fulvestrant+ Palbociclib seems to be active in patients whose tumour harbours ESR1 mutations. This study will confirm these data on this population and will allow us to identify if other gene alterations or a genomic signature can correlate with fulvestrant +palbociclib resistance.

NCT ID: NCT02942238 Not yet recruiting - Clinical trials for Postoperative Complications

Standardization of Laparoscopic Surgery for Right Hemi Colon Cancer (SLRC)

Start date: January 2017
Phase: N/A
Study type: Interventional

To standardize the surgery for advanced right hemi colon cancer with laparoscopy and investigate whether extended lymphadenectomy (CME) could improve disease-free survival in patients with right colon cancer, compared with D3 radical operation in laparoscopic colectomy.

NCT ID: NCT01798771 Not yet recruiting - Glioblastoma Clinical Trials

Intraoperative MRI and 5-ALA Guidance to Improve the Extent of Resection in Brain Tumor Surgery

IMAGER
Start date: March 2013
Phase: N/A
Study type: Interventional

The investigators hypothesize that the rate of radiologically complete resections of contrast-enhancing brain tumors following surgeries aided by use of 5-ALA induced fluorescence guidance and use of an intraoperative ultra-low field MRI is higher compared to surgeries aided by 5-ALA induced fluorescene alone.